-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SION-109 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SION-109 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SION-109 in Cystic Fibrosis Drug Details: SION-109 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – R-835 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R-835 in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. R-835 in Rheumatoid Arthritis Drug Details: R-835 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TRGFT-201 in Hematopoietic Stem Cell Transplantation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TRGFT-201 in Hematopoietic Stem Cell Transplantation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TRGFT-201 in Hematopoietic Stem Cell Transplantation Drug Details: TRGFT-201 is...
-
Analyst Opinions
Net Zero by 2050 – Industrial Decarbonization Gains Momentum (Vol.2)
Net Zero by 2050 Overview Businesses and tech giants globally are focusing on low-carbon products, renewables, and EVs to achieve net zero emissions. Key sectors such as aerospace, automotive, and technology are advancing sustainability through innovations in hydrogen, EVs, fuel cells, and smart energy solutions among others. The “Net Zero by 2050” report outlines decarbonization-related deals value and volume trends, VC investment activity and geographic trends, and leading investors. The report also provides facts and figures related to climate change,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CA-102N in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CA-102N in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CA-102N in Metastatic Colorectal Cancer Drug Details: CA-102N is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Budigalimab in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Budigalimab in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Drug...